Recent Updates
Recently added Catalysts

ABBV-932

Phase 2

Bipolar I or II Disorder | Small molecule | Psychiatry |AbbVie Inc.|Last Updated: Apr 7, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment200
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07220460Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II DisorderPHASE2 RECRUITING 200Sep 30, 2025Apr 1, 2027Apr 7, 202649 United States, Puerto Rico
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants Experiencing Adverse Events
Up to approximately 29 weeks

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
Up to week 26

Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

Number of Participants with Change from Baseline in Electrocardiogram (ECG)
Up to week 26

12-lead resting ECG will be recorded.

Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
Up to week 26

Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.

Change From Baseline in Simpson-Angus Scale (SAS)
Up to week 26

SAS (Simpson-Angus Scale): is a 10-item rating scale for assessment of antipsychotic-induced parkinsonism in both clinical practice and research settings. Minimum: 0 (no symptoms) Maximum: 40 (very severe symptoms; 10 items scored 0-4 each).

Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)
Up to week 26

AIMS (Abnormal Involuntary Movement Scale): assesses abnormal involuntary movements, such as tardive dyskinesia, associated with antipsychotic drugs; it measures facial, oral, extremities, and trunk movements, as well as the participant's awareness of abnormal movements. Minimum: 0 (no abnormal movements) Maximum: 42 (most severe; 7 items scored 0-4 each), some versions use 0-4 on 10 items for a max of 40/40.

Change From Baseline in Barnes Akathisia Rating Scale (BARS)
Up to week 26

BARS (Barnes Akathisia Rating Scale): is a 4-item rating scale used to assess drug-induced akathisia. The scale comprises items for rating the observable restless movements that characterize the condition, the subjective awareness of restlessness, and any distress associated with the akathisia. Minimum: 0 (no akathisia) Maximum: 14 (severe akathisia; 4 items scored, most items 0-3 or 0-5)

Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
Up to week 26

C-SSRS rates an individual's degree of suicidal ideation (SI) and behaviors on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent."

Change From Baseline in the Epworth Sleepiness Scale (ESS)
Up to week 26

ESS (Epworth Sleepiness Scale): is a scale that is intended to measure daytime sleepiness. Minimum: 0 (no sleepiness) Maximum: 24 (severe sleepiness; 8 items scored 0-3 each)

Change From Baseline in the Young Mania Rating Scale (YMRS)
Up to week 26

The YMRS (Young Mania Rating Scale): is an 11-item, clinician-rated scale that assesses manic symptoms based on the participant's perception of their condition over the previous 48 hours, as well as the physician's clinical observations during the interview. Minimum: 0 (no mania) Maximum: 60 (severe mania; 11 items, some scored 0-4, others 0-8)

Number of Participants with Abnormal Change in Ocular Examination
Up to week 26

Number of participants with abnormal change in ocular examinations in areas like best corrected visual acuity (BCVA), and refraction.

Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ABBV-932EXPERIMENTALParticipants will receive oral ABBV-932 for a 26-week treatment period followed by a 30-day follow-up
Interventions
NameTypeDescription
ABBV-932DRUGOral Capsule
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites49

Inclusion Criteria: * Body Mass Index (BMI) ≥ 18.0 to ≤ 40.0 kg/m\^2, inclusive. * Participants who currently meet the Diagnostic and Statistical Manual of Mental Disorders treatment (DSM-5-TR) criteria for bipolar I or II disorder without psychotic features based on the Mini International Neuropsy...

Countries:United StatesPuerto Rico
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07220460primaryCompletionDate: changed
LOWMay 24, 2026NCT07220460studyFirstPostDate: changed